Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Extracellular Phosphorylation of TIMP-2 by Secreted c-Src Tyrosine Kinase Controls MMP-2 Activity.

Sánchez-Pozo J, Baker-Williams AJ, Woodford MR, Bullard R, Wei B, Mollapour M, Stetler-Stevenson WG, Bratslavsky G, Bourboulia D.

iScience. 2018 Mar 23;1:87-96. doi: 10.1016/j.isci.2018.02.004. Epub 2018 Mar 23.

2.

Macromolecule-Network Electrostatics Controlling Delivery of the Biotherapeutic Cell Modulator TIMP-2.

Yamada Y, Chowdhury A, Schneider JP, Stetler-Stevenson WG.

Biomacromolecules. 2018 Apr 9;19(4):1285-1293. doi: 10.1021/acs.biomac.8b00107. Epub 2018 Mar 19.

3.

Tissue Inhibitor of Metalloprotease-2 (TIMP-2): Bioprocess Development, Physicochemical, Biochemical, and Biological Characterization of Highly Expressed Recombinant Protein.

Chowdhury A, Brinson R, Wei B, Stetler-Stevenson WG.

Biochemistry. 2017 Dec 12;56(49):6423-6433. doi: 10.1021/acs.biochem.7b00700. Epub 2017 Nov 28.

4.

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors.

Woodford MR, Truman AW, Dunn DM, Jensen SM, Cotran R, Bullard R, Abouelleil M, Beebe K, Wolfgeher D, Wierzbicki S, Post DE, Caza T, Tsutsumi S, Panaretou B, Kron SJ, Trepel JB, Landas S, Prodromou C, Shapiro O, Stetler-Stevenson WG, Bourboulia D, Neckers L, Bratslavsky G, Mollapour M.

Cell Rep. 2016 Feb 2;14(4):872-884. doi: 10.1016/j.celrep.2015.12.084. Epub 2016 Jan 21.

5.

The tumor microenvironment: the connective tissue/tumor cell/host organ system that modulates tumor progression.

Stetler-Stevenson WG.

Connect Tissue Res. 2015;56(5):343-4. doi: 10.3109/03008207.2015.1086622. No abstract available.

6.

c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells.

Dunn DM, Woodford MR, Truman AW, Jensen SM, Schulman J, Caza T, Remillard TC, Loiselle D, Wolfgeher D, Blagg BS, Franco L, Haystead TA, Daturpalli S, Mayer MP, Trepel JB, Morgan RM, Prodromou C, Kron SJ, Panaretou B, Stetler-Stevenson WG, Landas SK, Neckers L, Bratslavsky G, Bourboulia D, Mollapour M.

Cell Rep. 2015 Aug 11;12(6):1006-18. doi: 10.1016/j.celrep.2015.07.004. Epub 2015 Jul 30.

7.

Anti-inflammatory and antioxidant properties of Piper species: a perspective from screening to molecular mechanisms.

Kumar S, Malhotra S, Prasad AK, Van der Eycken EV, Bracke ME, Stetler-Stevenson WG, Parmar VS, Ghosh B.

Curr Top Med Chem. 2015;15(9):886-93. Review.

8.

Human cardiac fibroblast extracellular matrix remodeling: dual effects of tissue inhibitor of metalloproteinase-2.

Ngu JM, Teng G, Meijndert HC, Mewhort HE, Turnbull JD, Stetler-Stevenson WG, Fedak PW.

Cardiovasc Pathol. 2014 Nov-Dec;23(6):335-43. doi: 10.1016/j.carpath.2014.06.003. Epub 2014 Jun 21.

9.

Dietary intake of a plant phospholipid/lipid conjugate reduces lung cancer growth and tumor angiogenesis.

Shuman Moss LA, Jensen-Taubman S, Rubinstein D, Viole G, Stetler-Stevenson WG.

Carcinogenesis. 2014 Jul;35(7):1556-63. doi: 10.1093/carcin/bgu039. Epub 2014 Feb 7.

10.

Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.

Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C, Neckers L.

Mol Cell. 2014 Jan 23;53(2):317-29. doi: 10.1016/j.molcel.2013.12.007.

11.

Normalization of the tumor microenvironment: evidence for tissue inhibitor of metalloproteinase-2 as a cancer therapeutic.

Stetler-Stevenson WG, Gavil NV.

Connect Tissue Res. 2014 Jan-Feb;55(1):13-9. doi: 10.3109/03008207.2013.867339. Review.

12.

Molecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironment.

Remillard TC, Bratslavsky G, Jensen-Taubman S, Stetler-Stevenson WG, Bourboulia D.

Mol Cell Ther. 2014 Jun 3;2:17. doi: 10.1186/2052-8426-2-17. eCollection 2014. Review.

13.

Influence of Stromal Components on Lung Cancer Carcinogenesis.

Shuman Moss LA, Stetler-Stevenson WG.

J Carcinog Mutagen. 2013 Jun 25;13(8). doi: 10.4172/2157-2518.S13-008.

14.

SCNH2 is a novel apelinergic family member acting as a potent mitogenic and chemotactic factor for both endothelial and epithelial cells.

Fang C, Avis I, Bianco C, Held N, Morris J, Ylaya K, Hewitt SM, Aplin AC, Nicosia RF, Fung LA, Lewis JD, Stetler-Stevenson WG, Salomon DS, Cuttitta F.

Open J Clin Diagn. 2013 Jun;3(2):37-51.

15.

Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and Th17 T-helper cell subsets and is a direct STAT target gene.

Adamson A, Ghoreschi K, Rittler M, Chen Q, Sun HW, Vahedi G, Kanno Y, Stetler-Stevenson WG, O'Shea JJ, Laurence A.

PLoS One. 2013;8(3):e59367. doi: 10.1371/journal.pone.0059367. Epub 2013 Mar 26.

16.

An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells.

Han H, Bourboulia D, Jensen-Taubman S, Isaac B, Wei B, Stetler-Stevenson WG.

Oncogene. 2014 Feb 27;33(9):1198-206. doi: 10.1038/onc.2013.61. Epub 2013 Mar 11.

17.

TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells.

Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L, Stetler-Stevenson WG.

Oncotarget. 2013 Jan;4(1):166-76.

18.

Antagonism of VEGF-A-induced increase in vascular permeability by an integrin α3β1-Shp-1-cAMP/PKA pathway.

Kim SH, Cho YR, Kim HJ, Oh JS, Ahn EK, Ko HJ, Hwang BJ, Lee SJ, Cho Y, Kim YK, Stetler-Stevenson WG, Seo DW.

Blood. 2012 Dec 6;120(24):4892-902. doi: 10.1182/blood-2012-05-428243. Epub 2012 Oct 16.

19.

Matrix metalloproteinases: changing roles in tumor progression and metastasis.

Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG.

Am J Pathol. 2012 Dec;181(6):1895-9. doi: 10.1016/j.ajpath.2012.08.044. Epub 2012 Oct 12. Review.

20.

Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells.

Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, Neckers L.

Cell Cycle. 2012 Oct 1;11(19):3649-55. doi: 10.4161/cc.21926. Epub 2012 Aug 30.

21.

TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis.

Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J, Stetler-Stevenson WG.

J Immunother. 2012 Jul;35(6):502-12. doi: 10.1097/CJI.0b013e3182619c8e.

22.

Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli.

Gonçalves AN, Meschiari CA, Stetler-Stevenson WG, Nonato MC, Alves CP, Espreafico EM, Gerlach RF.

J Biotechnol. 2012 Jan;157(1):20-4. doi: 10.1016/j.jbiotec.2011.09.030. Epub 2011 Oct 5.

23.

Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.

Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B, Stetler-Stevenson WG.

Am J Pathol. 2011 Nov;179(5):2589-600. doi: 10.1016/j.ajpath.2011.07.035. Epub 2011 Sep 18.

24.

An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo.

Seo DW, Saxinger WC, Guedez L, Cantelmo AR, Albini A, Stetler-Stevenson WG.

Peptides. 2011 Sep;32(9):1840-8. doi: 10.1016/j.peptides.2011.08.010. Epub 2011 Aug 16.

25.

Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry.

Metaferia BB, Rittler M, Gheeya JS, Lee A, Hempel H, Plaza A, Stetler-Stevenson WG, Bewley CA, Khan J.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7337-40. doi: 10.1016/j.bmcl.2010.10.064. Epub 2010 Oct 21.

26.

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.

Bourboulia D, Stetler-Stevenson WG.

Semin Cancer Biol. 2010 Jun;20(3):161-8. doi: 10.1016/j.semcancer.2010.05.002. Epub 2010 May 12. Review.

27.

Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.

Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, Piper PW, Prodromou C, Pearl LH, Neckers L.

Mol Cell. 2010 Feb 12;37(3):333-43. doi: 10.1016/j.molcel.2010.01.005.

28.

TIMP-2 modulates VEGFR-2 phosphorylation and enhances phosphodiesterase activity in endothelial cells.

Lee SJ, Tsang PS, Diaz TM, Wei BY, Stetler-Stevenson WG.

Lab Invest. 2010 Mar;90(3):374-82. doi: 10.1038/labinvest.2009.136. Epub 2010 Jan 18.

29.

The prognostic value of TIMP-1 in multiple myeloma.

Guedez L, Stetler-Stevenson WG.

Leuk Res. 2010 May;34(5):576-7. doi: 10.1016/j.leukres.2009.10.005. Epub 2009 Oct 29. No abstract available.

30.

Overexpression of tissue inhibitors of metalloproteinase 2 up-regulates NF-kappaB activity in melanoma cells.

Sun J, Stetler-Stevenson WG.

J Mol Signal. 2009 Jul 23;4:4. doi: 10.1186/1750-2187-4-4.

31.

Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.

Alper O, Stetler-Stevenson WG, Harris LN, Leitner WW, Ozdemirli M, Hartmann D, Raffeld M, Abu-Asab M, Byers S, Zhuang Z, Oldfield EH, Tong Y, Bergmann-Leitner E, Criss WE, Nagasaki K, Mok SC, Cramer DW, Karaveli FS, Goldbach-Mansky R, Leo P, Stromberg K, Weil RJ.

Cancer Sci. 2009 Sep;100(9):1748-56. doi: 10.1111/j.1349-7006.2009.01244.x. Epub 2009 Jun 17.

32.

TIMP-2 disrupts FGF-2-induced downstream signaling pathways.

Seo DW, Kim SH, Eom SH, Yoon HJ, Cho YR, Kim PH, Kim YK, Han JW, Diaz T, Wei BY, Stetler-Stevenson WG.

Microvasc Res. 2008 Nov;76(3):145-51. doi: 10.1016/j.mvr.2008.07.003. Epub 2008 Jul 29.

33.

Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities.

Stetler-Stevenson WG.

Sci Signal. 2008 Jul 8;1(27):re6. doi: 10.1126/scisignal.127re6. Review.

34.

TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation.

Kim YS, Seo DW, Kong SK, Lee JH, Lee ES, Stetler-Stevenson M, Stetler-Stevenson WG.

Cancer Lett. 2008 Sep 28;269(1):37-45. doi: 10.1016/j.canlet.2008.04.020. Epub 2008 May 23.

35.

Hematopoiesis in mice is extremely resilient to wide variation in TIMP/MMP balance.

Haviernik P, Diaz MT, Haviernikova E, Tse W, Stetler-Stevenson WG, Bunting KD.

Blood Cells Mol Dis. 2008 Sep-Oct;41(2):179-87. doi: 10.1016/j.bcmd.2008.03.005. Epub 2008 May 19.

36.

TGF-beta signaling preserves RECK expression in activated pancreatic stellate cells.

Lee H, Lim C, Lee J, Kim N, Bang S, Lee H, Min B, Park G, Noda M, Stetler-Stevenson WG, Oh J.

J Cell Biochem. 2008 Jun 1;104(3):1065-74. doi: 10.1002/jcb.21692.

PMID:
18300271
37.
38.

Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.

Horak CE, Lee JH, Elkahloun AG, Boissan M, Dumont S, Maga TK, Arnaud-Dabernat S, Palmieri D, Stetler-Stevenson WG, Lacombe ML, Meltzer PS, Steeg PS.

Cancer Res. 2007 Aug 1;67(15):7238-46.

39.

TIMP-2 promotes cell spreading and adhesion via upregulation of Rap1 signaling.

Chang H, Lee J, Poo H, Noda M, Diaz T, Wei B, Stetler-Stevenson WG, Oh J.

Biochem Biophys Res Commun. 2006 Jul 7;345(3):1201-6. Epub 2006 May 15.

PMID:
16716258
40.

TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118.

Oh J, Diaz T, Wei B, Chang H, Noda M, Stetler-Stevenson WG.

Oncogene. 2006 Jul 13;25(30):4230-4. Epub 2006 Feb 20.

41.

Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells.

Seo DW, Li H, Qu CK, Oh J, Kim YS, Diaz T, Wei B, Han JW, Stetler-Stevenson WG.

J Biol Chem. 2006 Feb 10;281(6):3711-21. Epub 2005 Dec 2.

42.

Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.

Larsen MB, Stephens RW, Brünner N, Nielsen HJ, Engelholm LH, Christensen IJ, Stetler-Stevenson WG, Høyer-Hansen G.

Scand J Immunol. 2005 May;61(5):449-60.

43.

Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta.

Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB.

J Cell Sci. 2005 May 15;118(Pt 10):2143-53. Epub 2005 Apr 26.

44.

TIMP-2: an endogenous inhibitor of angiogenesis.

Stetler-Stevenson WG, Seo DW.

Trends Mol Med. 2005 Mar;11(3):97-103. Review.

PMID:
15760767
45.

Role of human cripto-1 in tumor angiogenesis.

Bianco C, Strizzi L, Ebert A, Chang C, Rehman A, Normanno N, Guedez L, Salloum R, Ginsburg E, Sun Y, Khan N, Hirota M, Wallace-Jones B, Wechselberger C, Vonderhaar BK, Tosato G, Stetler-Stevenson WG, Sanicola M, Salomon DS.

J Natl Cancer Inst. 2005 Jan 19;97(2):132-41.

PMID:
15657343
46.

Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK.

Oh J, Seo DW, Diaz T, Wei B, Ward Y, Ray JM, Morioka Y, Shi S, Kitayama H, Takahashi C, Noda M, Stetler-Stevenson WG.

Cancer Res. 2004 Dec 15;64(24):9062-9.

47.

CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells.

Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, Kelly K.

Blood. 2005 Apr 1;105(7):2836-44. Epub 2004 Dec 2.

48.

Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation.

Haviernik P, Lahoda C, Bradley HL, Hawley TS, Ramezani A, Hawley RG, Stetler-Stevenson M, Stetler-Stevenson WG, Bunting KD.

Oncogene. 2004 Dec 9;23(57):9212-9.

PMID:
15516987
49.

Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.

Guedez L, Martinez A, Zhao S, Vivero A, Pittaluga S, Stetler-Stevenson M, Raffeld M, Stetler-Stevenson WG.

Blood. 2005 Feb 15;105(4):1660-8. Epub 2004 Oct 12.

50.

Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth.

Martínez A, Zudaire E, Portal-Núñez S, Guédez L, Libutti SK, Stetler-Stevenson WG, Cuttitta F.

Cancer Res. 2004 Sep 15;64(18):6489-94.

Supplemental Content

Loading ...
Support Center